Watchlist Price Alert

Arcturus Therapeutics In... (ARCT)

NASDAQ: ARCT · Real-Time Price · USD

11.66

0.02 (0.17%)

At close: May 16, 2025, 3:59 PM

11.65

-0.09%

After-hours: May 16, 2025, 04:20 PM EDT

0.17% (1D)

Bid	11
Market Cap	316.23M
Revenue (ttm)	135.17M
Net Income (ttm)	-51.35M
EPS (ttm)	-2.71
PE Ratio (ttm)	-4.3
Forward PE	-3.02
Analyst	Buy

Ask	13
Volume	265,546
Avg. Volume (20D)	434,270
Open	11.59
Previous Close	11.64
Day's Range	11.53 - 11.87
52-Week Range	8.04 - 45.00
Beta	2.37

About ARCT

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol ARCT

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for ARCT stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Earnings Surprise

Arcturus Therapeutics has released their quartely earnings on May 12, 2025:

Revenue of $29.38M exceeds estimates by $6.03M, with -22.70% YoY decline.

EPS of -0.52 exceeds estimates by 0.58, with 48.00% YoY growth.

Why Price Moved

4 days ago

+2.33%

Arcturus Therapeutics shares are trading higher af... Unlock content with Pro Subscription

2 months ago

-0.5%

Arcturus Therapeutics shares are trading lower after the company reported Q4 financial results and missed its EPS and revenue estimates.

News

3 days ago · zacks.com

Wall Street Analysts Believe Arcturus Therapeutics (ARCT) Could Rally 503.6%: Here's is How to Trade

The consensus price target hints at a 503.6% upside potential for Arcturus Therapeutics (ARCT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in ear...

5 days ago · seekingalpha.com

Arcturus Therapeutics Holdings Inc. (ARCT) Q1 2025 Earnings Call Transcript

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT ) Q1 2025 Earnings Conference Call May 12, 2025 4:30 PM ET Company Participants Neda Safarzadeh - Vice President, Head of Investor Relations, Public Re...

5 days ago · zacks.com

Arcturus Therapeutics (ARCT) Reports Q1 Loss, Tops Revenue Estimates

Arcturus Therapeutics (ARCT) came out with a quarterly loss of $0.52 per share versus the Zacks Consensus Estimate of a loss of $1.58. This compares to loss of $1 per share a year ago.

1 week ago · zacks.com

Earnings Preview: Arcturus Therapeutics (ARCT) Q1 Earnings Expected to Decline

Arcturus Therapeutics (ARCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 weeks ago · businesswire.com

Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 12, 2025

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the developm...

1 month ago · zacks.com

Arcturus Gets FDA's Fast Track Tag for Influenza Vaccine Candidate

The FDA bestows a Fast Track designation to ARCT's sa-mRNA vaccine candidate, ARCT-2304, for active immunization to prevent pandemic influenza A virus H5N1.

2 months ago · seekingalpha.com

Arcturus Therapeutics Holdings Inc. (ARCT) Q4 2024 Earnings Call Transcript

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT ) Q4 2024 Earnings Conference Call March 6, 2025 4:30 PM ET Company Participants Neda Safarzadeh - Vice President, Head of Investor Relations Joe Payne...

2 months ago · zacks.com

Arcturus Therapeutics (ARCT) Reports Q4 Loss, Misses Revenue Estimates

Arcturus Therapeutics (ARCT) came out with a quarterly loss of $1.11 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.32 per share a year ago.

2 months ago · businesswire.com

Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2024 Financial Update and Pipeline Progress

2 months ago · businesswire.com

Arcturus Therapeutics to Present at Leerink's Global Healthcare Conference 2025

Load More News